Illumina Wants 'Entirely Derivative' Antitrust Suit Paused

Law360 (February 23, 2021, 9:13 PM EST) -- Illumina wants a California federal judge to pause a competitor's antitrust suit so the gene-sequencing behemoth can first pursue its patent infringement suit against that same rival.

The antitrust claims from Complete Genomics, also known as CGI, accusing Illumina of stifling competition with fraudulently obtained patents and "baseless" infringement litigation, are simply a reprise of the company's defenses against Illumina's infringement assertions over DNA sequencing patents, Illumina said Friday. That means, according to Illumina, that its patent infringement claims — the latest in a decade-long international patent war between the companies — should go first because the antitrust allegations "are derivative of issues that will be...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!